ÄÛBÑо¿Ôº

Melanoma: (Dieng et al., 2018; n = 164; mean age = 58.2 (12.1))

• Mean utility score (SD) = 0.77 (0.2)

Melanoma: (Dieng et al., 2018)

• Excellent: Cronbach¡¯s Alpha = 0.85

Concurrent Validity:

Melanoma: (Dieng et al., 2018)

• Adequate concurrent validity between the overall scores on the AQoL-8D and the Functional Assessment of Cancer Treatment - Melanoma (FACT-M) (r = 0.57)
• Excellent concurrent validity between the AQoL-8D mental health dimension and the FACT-M overall score (r = 0.61)
• Adequate concurrent validity between the AQoL-8D mental health dimension and the FACT-M emotional well-being component (r = 0.51)

Convergent Validity:

Melanoma: (Dieng et al., 2018)

• Significant difference between reported fear of cancer recurrence inventory (FCRI) severity scores among low and high FCRI groups for both the AQoL-8D (f = 9.74, p = 0.002) and FACT-M (f = 9.98, p = 0.002)
• Significant difference between FCRI groups in the AQoL-8D mental health dimension (f = 22.84, p < 0.001) and the emotional well-being dimension of the FACT-M (f = 38.81, p < 0.001)

Discriminant Validity:

Melanoma: (Dieng et al., 2018)

• No significant difference between FCRI groups in the AQoL-8D super physical dimension (f = 0.04, p = 0.84) and a significant difference between the groups on the physical well-being component of the FACT-M (f = 5.69, p = 0.02)

Melanoma: (Dieng et al., 2018)

• Adequate ceiling effect of 0.6% and floor effect of 3.7% found

Spinal Cord Injury: (Whitehurst et al., 2016; n = 364 (63% male); able to walk n = 119; unable to walk n = 245; 1-10 years post injury n = 109, 10+ years post injury n = 255; ASIA classification A (n = 115), B (n = 31), C (n = 119), D (n = 69), E (n = 8), Uncertain (n = 22); Tetraplegia n = 175, Paraplegia n = 189; mean age = 50.40 (13.2))

Descriptive statistics for the AQoL-8D by self-reported ability to walk

^aOne respondent failed to complete all items.

Asthma: (Kaambwa et al., 2017; n = 856; Australia (n = 141), United States (n = 150), United Kingdom (n = 150), Canada (n = 138), Norway (n = 130), Germany (n = 147); age = 18+)

• Mean (SD): 0.69 (0.20)
• Median (IQR): 0.72 (0.54¨C0.86)

Convergent Validity:

Asthma: (Kaambwa et al., 2017)

• Excellent convergent validity between Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and AQoL-8D (r = 0.642)

Mixed Population: (Richardson et al., 2014; Australian sample n = 1,430, healthy public n = 265, patient n = 1,165; US sample n = 1,460, healthy public n = 321, patient n = 1,139)

• Acceptable test-retest reliability: (ICC = .91 Base to 2-week, ICC = .89 Base to 4-week)

Mixed Population: (Richardson et al., 2014)

• Excellent internal consistency (Cronbach¡¯s alpha = 0.96)

Predictive Validity:

Mixed Population: (Richardson et al., 2014)

• Adequate and at least as great as the predictive validity of other MAU instruments with an average of 43% (Australian sample) and 36% (US population) deviation from perfect prediction. Overall average deviation was 49.2% (p 94).

Convergent Validity:

Mixed Population: (Richardson et al., 2014)

• Excellent convergent validity with EuroQoL-5 Dimension (EQ-5D), Health Utilities Index 3 (HUI 3), and SF 6D (r = 0.68-0.79)
• Adequate to excellent convergent validity with 15D (r = 0.57-0.61)
• Adequate convergent validity with Quality of Well-Being (QWB) (r = 0.55)

Mixed Population (Richardson et al., 2016, n = 7,933; cancer (n = 772); heart disease (n = 943); other populations not reported)

• Adequate to Excellent construct validity (r = 0.48-0.75)

Correlations of AQoL-8D With Indices of Physical and Psychosocial Content and Preferences by Patient Group

Strong content validity based on comparison to the eight dimensions of the SF-36, ¡°the most widely used non-utility measure of health- related quality of life¡± (p 88) and above average Pearson coefficient scores in most areas when compared with the other MAU (multi-attribute utility) instruments (Richardson et al., 2014, p. 92)

Assessment has high face validity as it includes items in all categories under physical and psychosocial dimensions. Richardson et al. (2014) concluded that it ¡°has high face validity and particularly in the psychosocial dimensions, which include 24 of its 35 items.¡± (p. 90-91)

Mixed Population: (Richardson et al., 2014)

• Adequate ceiling (2.60% in Australian sample and 8.10% in US sample) and floor effects (10.60% in Australian sample and 10.10% in US sample)

Mixed Population: (Richardson et al., 2016)

• Moderate to Large effect size by patient group (°ä´Ç³ó±ð²Ô¡¯²õ d = 0.62 ¨C 2.68)

 Effect Size of AQol-8D by Patient Group

Dementia: (Engel et al., 2020; person with dementia n = 9; caregiver n = 17; person with dementia mean age = 74.9 , caregiver mean age = 68)

• Study participants identified a range of aspects of quality of life they perceived as important. These were summarized into nine domains: Activity, Autonomy, Cognition, Communication, Coping, Emotions, End-of-life, Physical Functioning, and Relationships.

Dementia: (Engel et al., 2020)

• Tested face validity with people with mild dementia and caregivers and reported that " the AQoL-8D (35 items) showed the greatest overlap with domains of QoL that were considered as important, although some redundancy was also noted, given it is a generic measure with some questions being less applicable to people living with dementia.¡±

Obesity: (Campbell et al., 2016; n = 33; mean age = 56 (11); mean time post-surgery = 6 (6) years)

Descriptive statistics for AQoL-8D utility value

Convergent Validity:

Obesity: (Campbell, 2016)

• Excellent correlation between the utilities for the EQ-5D-5L and AQoL-8D (r = 0.68, p < 0.001).

Obesity: (Campbell, 2016)

• Excellent floor and ceiling effects found (0%)